Abstract Genes coding for the α5, α3, and 4 subunits (CHRNA5, CHRNA3, and CHRNB4) of the neuronal nicotinic acetylcholine receptors (nAChRs) are clustered on chromosome 15q24. Linkage of this chromosomal region to autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), an idiopathic partial epilepsy, was reported in one family. Moreover, mutations in other neuronal nAChR subunit genes coding for the α4 (CHRNA4) and the 2 (CHRNB2) subunits were associated with ADNFLE. Apart from the exon-intron structure of CHRNA3, the genomic organization of this gene cluster was unknown, making comprehensive mutational analyses impossible. The genomic structure of CHRNA5 and CHRNB4 is here reported. Moreover, two hitherto unknown introns were identified within the 3Ј untranslated region of CHRNA3, causing a partial tail-to-tail overlap with CHRNA5. Four novel intragenic polymorphisms were identified and characterized in the cluster.
Introduction
Neuronal nicotinic acetylcholine receptors (nAChRs) are multisubunit, ligand-gated ion channels expressed in the peripheral and central nervous systems (Clementi et al. 2000) . They are formed by different combinations of homologous subunits, assembled as pentameric structures giving rise to an aqueous central channel. The receptor subunits are encoded by a gene family composed of at least 12 members classified as α subunits (α2 to α10) and subunits ( 2 to 4) (Le Novere and Changeux 1995; Lustig et al. 2001) . Alpha subunits, characterized by the presence of two adjacent cysteines in their extracellular domain, constitute the major component of the acetylcholine binding site, while subunits have a mainly structural role, although they have been shown to contribute to ligand binding profiles (McGehee 1999) . With the exception of α7 and α9 subunits that can assemble into homopentamers, neuronal nAChRs result from the assembly of five subunits, in a stoichiometry of two α to three . The large number of different subunits giving rise to various combinations, including those containing more than one type of α and/or subunit (McGehee 1999), can produce a huge variety of nAChRs, with different biophysical and pharmacological properties. However, the predominant forms are α4 2 and α4α5 2 in the central nervous system and α3 4 or α3α5 4 in the peripheral nervous system (McGehee 1999) .
Qualitative or quantitative alterations of the nAChRs can cause brain diseases, including idiopathic epilepsies, schizophrenia, Alzheimer disease, and Parkinson disease (Clementi et al. 2000) . To date, the pathogenetic mechanism has been elucidated only for autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE, MIM#600513, MIM*603204, and MIM#605375), a partial idiopathic epilepsy characterized by clusters of brief nocturnal motor seizures with a frontal lobe semiology (for a review, see Scheffer 2000) . Mutations in two members of the nAChR gene family (CHRNA4 and CHRNB2, coding for the α4 and 2 subunits, respectively) were demonstrated to be involved in this syndrome (Scheffer and Berkovic 2000; De Fusco et al. 2000; Phillips et al. 2001 ). All identified mutations affect amino acids that line the aqueous pore within the ion channel structure and determine an alteration of the functional properties of the receptor (De Fusco et al. 2000; Scheffer 2000; Phillips et al. 2001) , supporting the concept that idiopathic epilepsies are, at least in part, ion channel disorders. However, mutations in CHRNA4 and CHRNB2 account only for a small proportion of ADNFLE cases (Tenchini et al. 1999) .
Genes for additional subunits of the nAChR expressed in brain are obvious candidates for mutation in families and sporadic cases, in which no involvement of CHRNA4 or CHRNB2 can be demonstrated by linkage or mutational analyses. In particular, a third locus for ADNFLE was reported on 15q24, a chromosome region that contains the CHRNA5/A3/B4 gene cluster coding for the α5, α3, and 4 subunits, respectively. However, neither the gene nor the mutation involved was identified (Phillips et al. 1998) .
Although cDNA sequences for nAChR subunits have been analyzed in humans and in a number of different species, the genomic structure has been described only for CHRNA3, CHRNA4, CHRNA7, CHRNA10, and CHRNB2, coding for the α3, α4, α7, α10, and 2 subunits, respectively (Steinlein et al. 1996; Gault et al. 1998; Rempel et al. 1998; Lustig et al. 2001) . The overall genomic organization of these genes is conserved and characterized by the presence of six exons, except for CHRNA7, which, both in humans and chick, consists of ten exons as the result of partial gene duplication.
In the present paper, the genomic organization of CHRNA5 and CHRNB4 together with the sequences of exon-intron boundaries are reported. Two novel introns interrupting the 3Ј untranslated region (UTR) of CHRNA3 were identified, and CHRNA3 and CHRNA5 were shown to partially overlap at their 3Ј ends. Moreover, four novel polymorphisms were identified and their allele frequencies estimated in an Italian population sample.
Subjects and methods

Sample composition and DNA extraction
Clinical characteristics of analyzed ADNFLE probands were previously described (Oldani et al. 1998; Tenchini et al. 1999) . All examined subjects gave informed consent in writing before blood withdrawal. Genomic DNA was extracted from blood samples using the Nucleon BACC1 kit (Amersham Pharmacia Biotech, Uppsala, Sweden). DNAs extracted from normal healthy Italian individuals of both sexes without sleep disorders were used to calculate allele frequencies of the identified polymorphisms.
Long-range polymerase chain reaction Long-range inter-exon polymerase chain reaction (PCR) was accomplished using the Expand 20 kb plus PCR system kit (Roche Diagnostics, Monza, Italy) and a Personal Cycler (Biometra, Göttingen, Germany). Thermal conditions were 10 cycles of 92°C for 10 s, 60°-64°C for 30s, and 68°C for 10-18 min, preceded by 2 min at 92°C and followed by 20 additional cycles with a time increment of 10 s for each cycle in the elongation step. A final incubation at 68°C for 7 min was also performed.
DNA sequencing
PCRs for the generation of templates were performed on 50-100ng of genomic DNA in a standard 50 µl volume containing 1x reaction buffer (10mM Tris-HCl, pH 8.3, 50 mM KCl, 0.001% gelatin), 1.5mM MgCl 2 , 0.4 µM of each primer, 200 µM dNTPs, and 2U RED Taq DNA polymerase (Sigma, St. Louis, MO, USA) on a PTC-100 (MJ Research, Watertown, MA, USA) thermal cycler. Thermal conditions were 30-35 cycles of 95°C for 30s, 52°-60°C for 30 s and 72°C for 20-60s, preceded by 3 min at 95°C and followed by a final incubation at 72°C for 10 min.
Sequencing was performed on both strands, directly on purified PCR products, using the BigDye terminator kit and an automated ABI-310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Factura and Sequence Navigator softwares (Applied Biosystems) were used for mutation detection. Alignments were performed by the BLAST algorithm (http://www.ncbi.nlm.nih.gov/BLAST/).
Primers
Primers used for inter-exon PCR were designed on the basis of known sequences of the CHRNA5 and CHRNB4 cDNAs (GenBank, accession numbers: NM_000745 and NM_000750) and are listed in Tables 1 and 2 , together with primers used for exon amplification and mutational screening of CHRNA5 and CHRNB4. Primers used to amplify CHRNA3 exons were designed on the basis of the known genomic sequences of CHRNA3 (GenBank, accession numbers: AJ007783-AJ007787) and can be provided on request. All primers were from Life Technologies (Inchinnan, Paisley, UK).
Detection of the short tandem repeat (STR) polymorphism
The tetranucleotide-repeat marker identified in intron 2 of CHRNB4 (CHRNB4.IVS2.STR) was amplified using the primer pair B4STR-F (5Ј-AAAGATCACACCACTGCC CT-3Ј) and 6Fam-B4STR-R (5Ј-CATCCTATCTGAGAA ATCTTCC-3Ј) in a Personal Cycler (Biometra). Standard 20µl-PCR reactions contained 50 ng genomic DNA, 1x PCR reaction buffer (20 mM TrisHCl, pH 8.4, 50 mM KCl), 1.5 mM MgCl 2 , 200 µM of each dNTP, 0.4 µM of each primer, and 0.5 U Platinum Taq DNA polymerase (Life Technologies). The thermal profile consisted of: an initial denaturation step of 95°C for 3min followed by 30 cycles of 95°C for 30s, 60°C for 30 s, and 72°C for 30s. A final extension of 10 min at 72°C was added after the last cycle. Amplified products were separated using an ABI-310 Genetic Analyzer; allele sizing was performed by Genescan 3.1 software (Applied Biosystems).
Detection of single-nucleotide polymorphisms (SNPs)
Screening for the TϾC polymorphism identified at position Ϫ5 in intron 3 of CHRNA3 (CHRNA3.IVS3.Ϫ5TϾC) was performed by TaqI digestion of PCR products amplified using the following primers: 5Ј-GGAAGTAAAACCA GGCTGATTC-3Ј (sense, position 28-49) and 5Ј-AAGG CCAGGTTTTAAGCACAGT-3Ј (antisense, position 284-263) (numbering according to CHRNA3 exon 4 sequence, GenBank accession number AJ007785). Digestion products were electrophoresed on 2.5% agarose gels. CHRNA5.IVS1.Ϫ34TϾC and CHRNA5.IVS3.ϩ211AϾG polymorphisms were analyzed by direct sequencing of PCR-amplified genomic DNA.
Results
CHRNA5 and CHRNB4 genomic structures
The exon-intron organization of CHRNA5 and CHRNB4 was identified by a PCR-based approach. The putative positions of exon-intron junctions were deduced by multiple alignment of several neuronal nAChR subunit genes. Primers were designed taking care to avoid the putative splicing junctions in order to amplify all introns of both genes. Introns 1, 4, and 5 of CHRNA5 and introns 1, 4, and 5 of CHRNB4 were individually amplified by inter-exon PCR, while introns 2 and 3 were obtained as a single fragment for each gene.
The genomic structure of both genes was defined ( Fig. 1) , and the sequence of all splicing junctions was obtained by partial sequencing of PCR product ends and by evaluation of fragment lengths by gel electrophoresis. The genomic size was about 25 and 17 kb for CHRNA5 and CHRNB4, respectively. Both genes are composed of six exons and five introns, in agreement with the overall structure of known nAChR genes. All splice sites in both genes are in accordance with the consensus GT-AG (Shapiro and Senapathy 1987) . Nucleotide sequences of CHRNA5 and CHRNB4 have been submitted to the EMBL nucleotide sequence database (accession numbers AJ306481-AJ306486 and AJ306454-AJ306459, respectively).
Characterization of a novel tetranucleotide-repeat marker in intron 2 of CHRNB4 Sequencing of CHRNB4 intron 2 revealed the presence of a short tandem repeat (STR) consisting of a tetranucleotide (GAAA) n repeat, located about 1kb upstream of the exon The position of the novel tetranucleotide-repeat marker in intron 2 of CHRNB4 is indicated 3 acceptor splice site. To verify whether this sequence represented a polymorphic site, a primer pair (B4STR-F and 6Fam-B4STR-R) flanking the repeat was designed. The reverse primer was 5Ј-labeled with 6-Fam. One hundred two unrelated healthy Italian individuals were genotyped by PCR amplification from genomic DNA; PCR products were analyzed using an ABI-310 Genetic Analyzer. A total of ten different alleles were detected, ranging from 245 to 305 bp. Allele lengths and frequencies of this novel CHRNB4 marker (CHRNB4.IVS2.STR) are reported in Table 3 . Heterozygosity and polymorphism information content (PIC) values are 0.7020 and 0.6549, respectively.
Mutational analysis
The search for mutations in the CHRNA5/A3/B4 genes was performed in five unrelated ADNFLE probands. All subjects were chosen from ADNFLE families (nos. 5, 7, 12, 18, and 35) (Oldani et al. 1998; Tenchini et al. 1999) in which segregation analysis excluded linkage to CHRNA4 and CHRNB2 and showed compatibility with linkage to 15q24 (data not shown). Full sequencing of both strands of exonic regions and exon-intron boundaries of the three genes did not detect any mutation in the analyzed patients.
Single-nucleotide polymorphisms (SNPs) in CHRNA3 and CHRNA5
As a result of sequence analysis of ADNFLE probands, three novel bi-allelic polymorphisms in the CHRNA3 and CHRNA5 genes were detected and designated following the recommendations of Antonarakis (1998) . One SNP was identified in intron 3 of CHRNA3 and consisted of a T to C transition at nucleotide position Ϫ5 (CHRNA3.IVS3.Ϫ5TϾC). This nucleotide variation probably does not alter the corresponding acceptor splice site, since intronic position Ϫ5 can be represented by either a C or a T (Shapiro and Senapathy 1987) . As this transition abolishes a TaqI restriction site, screening for this polymorphism was performed by PCR amplification of the relevant genomic fragment followed by TaqI restriction digestion in a control population of 60 unrelated healthy individuals from northern Italy. The remaining two SNPs were identified in CHRNA5 and consisted of a T to C transition at position Ϫ34 in intron 1 (CHRNA5.IVS1.Ϫ34TϾC) and an A to G transition at position ϩ211 in intron 3 (CHRNA5.IVS3.ϩ211AϾG). As they did not alter any known restriction site, their frequency was estimated by sequencing genomic DNAs at the relevant positions of the same control individuals as above. The frequencies of the rare allele and the heterozygosity and PIC values of each polymorphism are reported in Table 4 .
Identification of two novel CHRNA3 introns
The previously reported genomic organization of CHRNA3 consisted of six exons and five introns (Rempel et al. 1998) . Amplification of exon 6 of this gene for mutational screening with the primer pair A3ex6F (5Ј-CTGCAACGTGT TGATTACATCTT-3Ј) and A3ex6R (5Ј-TTCATAGCCC AGGTTCTTGATC-3Ј) produced a 3.3 kb-fragment, approximately 2.85 kb larger than that predicted on the basis of the CHRNA3 cDNA sequence. The possible occurrence of intervening sequences was therefore hypothesized. Direct sequencing of this 3.3 kb-fragment and subsequent alignment with the published cDNA of CHRNA3 (Mihovilovic and Roses 1991) demonstrated the presence of two additional introns, located at cDNA positions 1576 and 1674 (numbering from the first nucleotide of the ATG start codon, according to GenBank accession number M37981) (Fig. 2) . The newly identified introns 6 and 7 were shown by sequencing to span 2535 and 722 bp, respectively, extending CHRNA3 by approximately an additional 3.2 kb (intron 6 ϩ intron 7) at its 3Ј end. Because the previously described exon 6 turns out to be interrupted by two additional introns, the CHRNA3 exon-intron structure comprises eight exons and seven introns. The presence of an antisense Alu repeat spanning from intron 6 to intron 7 and containing the whole CHRNA3 exon 7 was also identified by BLAST search (Fig. 2) .
Tail-to-tail overlap between CHRNA3 and CHRNA5
While the CHRNA3/CHRNB4 intergenic region was shown to span about 4 kb in humans (Fornasari et al. 1997 ), the precise distance between the 3Ј ends of CHRNA5 and CHRNA3 was unknown. Since we observed that CHRNA3 extends for an additional 3.2 kb at its 3Ј end and CHRNA5 and CHRNA3 were previously reported to be divergently transcribed (Flora et al. 2000a ), the existence of a possible overlap between them was explored. To this purpose, an alignment of the 3Ј regions of the two genes was performed. This analysis identified an overlapping region of 466 bp, corresponding to the whole CHRNA5 exon 6 together with 37 bp of the 3Ј end of intron 5 on one strand and to the entire CHRNA3 exon 8 plus 329 bp of intron 7 on the opposite strand. A schematic representation of the CHRNA5 and CHRNA3 3Ј ends together with the sequence of the overlapping region is shown in Fig. 3 . In order to confirm the existence of a partial tail-to-tail overlap between CHRNA5 and CHRNA3, a PCR assay on genomic DNA using two sense primers located in the 3Ј region of intron 5 of both genes was also performed. A PCR product of the expected size (about 3.3 kb) was obtained. The cDNAs of CHRNA5 and CHRNA3 share a 100 bp-region (corresponding to amino acids 416-448, including the first nucleotide of codon 449) of CHRNA5 and the part immediately upstream of the polyA signal in the 3ЈUTR of CHRNA3. In order to verify whether the genomic arrangement of CHRNA5 and CHRNA3 was conserved in other mammalian species, a PCR reaction on rat genomic DNA using rat-specific sense primers located in exon 6 of both genes was performed. A fragment of about 6 kb was obtained and partially sequenced at both ends. This analysis showed that the 3ЈUTRs of the cDNAs of CHRNA5 (1435 bp, GenBank accession number NM_017078) and CHRNA3 (282 bp, GenBank accession number L31621) are uninterrupted by introns, demonstrating that the two genes are not overlapped in rats. No complementarity between the two sequences was detected.
Discussion
In recent years, neuronal nAChRs have been involved in the pathogenesis of or identified as potential therapeutic targets in several neurological disorders such as idiopathic epilepsies (for a review, see Scheffer and Berkovic 2000) , Alzheimer disease (for a review, see James and Nordberg 1995) , Parkinson disease (Aubert et al. 1992; Schroder et al. 1995) , and schizophrenia (Freedman et al. 1997) . In particular, nAChR genes CHRNA4 and CHRNB2 have been reported to be involved in the pathogenesis of ADNFLE (Scheffer and Berkovic 2000; De Fusco et al. 2000; Phillips et al. 2001) . Precise information on the genomic organization of human neuronal nAChR subunit genes as well as on the primers and conditions for PCR amplifications from genomic DNA are prerequisites for mutational screenings. Here we report detailed data on the genomic organization of CHRNA5/A3/B4, clustered on chromosome 15q24. Only the structure of CHRNA3 was previously reported, although its exact genomic size had not been evaluated (Rempel et al. 1998 ). The exon-intron structures of CHRNA5 and CHRNB4 were identified and shown to be characterized by the presence of six exons and five introns, as observed for other nAChR coding genes (e.g., CHRNA4 and CHRNB2) (Steinlein et al. 1996; Rempel et al. 1998) . Moreover, partial sequences of the 5Ј and 3Ј ends of each intron were determined for both genes. During the final stage of this work, a large (about 179.4kb) genomic clone (RP11-335K5) containing the CHRNA5/A3/B4 cluster was deposited in GenBank (accession number AC067863). It was a draft sequence fragmented in 28 uncomplete and unordered pieces, which were reduced to ten in a very recent revision of the same clone. Alignments of the nucleotide sequences of the CHRNA5 and CHRNB4 intronic regions reported in the present paper with the above mentioned RP11-335K5 clone revealed a perfect identity. Moreover, three small undetermined regions in AC067863, located in CHRNA5 introns 2 and 5, were resolved by our group as poly-thymidine stretches.
Knowledge of the exon-intron structure as well as of the splicing junctions made it possible to perform a comprehensive mutational screening in five unrelated ADNFLE patients belonging to families for which segregation analysis excluded linkage to CHRNA4 and CHRNB2 and for which no clear exclusion of association to the 15q24 region could be demonstrated by haplotype analysis. No mutations responsible for ADNFLE were found, indicating that these genes may not be responsible for this syndrome in the analyzed families. Nevertheless, given the genetic heterogeneity of ADNFLE (Oldani et al. 1998; Phillips et al. 1998 ), a (Rempel et al. 1998 ) is in light gray. Thick arrows represent Alu sequences. A3ex6F and A3ex6R primers used to amplify the 3Ј region of CHRNA3 are indicated Fig. 3A-C larger patient cohort should be analyzed in order to exclude these genes as candidates for this disease.
Four novel polymorphisms (three SNPs and one STR) were identified in the CHRNA5/A3/B4 cluster. All were located in intronic regions. Each clustered gene is marked by at least one polymorphism. Frequencies of the identified polymorphisms were all fairly high with heterozygosity values ranging from 0.3942 to 0.7020. They therefore represent suitable markers for future association and linkage analyses to these genes.
Amplification of the CHRNA3 3ЈUTR identified two hitherto unnoticed introns, interrupting the 3ЈUTR. CHRNA3 therefore displays a genomic structure (eight exons and seven introns) peculiar among the nAChR gene family. Exon 7 of CHRNA3 is spliced out within an antisense Alu repeat which, on the basis of the nucleotides found at diagnostic positions shared by subfamily members, belongs to the Alu-Sp subfamily (Batzer et al. 1996) . It is interesting to note that an antisense Alu repeat located within CHRNA3 intron 5 was previously demonstrated to be inserted in the CHRNA3 mRNA by alternative splicing, giving rise to exon 5a (Mihovilovic et al. 1993 ). This transcriptional variant carries an in-frame stop codon and is expressed at low levels in tissues expressing the normal α3 transcript. An alignment of the newly identified AluSp sequence, located across exon 7 of CHRNA3, with that present in intron 5 of the same gene and belonging to the closely related Alu-Sx subfamily, showed an identity of 77%. Alu elements usually contain several potential splice sites (Ohshima and Gotoh 1987) . Comparison of the two transcribed CHRNA3 Alu sequences showed that in both cases the same donor splice site was used, while the acceptor sites were different, the exon 7 acceptor site being 25 nucleotides downstream from that used for the alternative splicing of exon 5a.
BLAST searches in the human expressed sequence tag (EST) database identified CHRNA3 ESTs lacking exon 7, indicating the occurrence of an alternative splicing of CHRNA3 exon 7.
CHRNA3 and CHRNA5, which are encoded on opposite DNA strands, were shown for the first time to share a 466 bp-region at their 3Ј ends. This tail-to-tail overlap produces, at the mRNA level, a 100 bp-region of complementarity between CHRNA5 and CHRNA3 mature transcripts. Several pairs of genes are arranged in a similar (tail-to-tail) overlapping manner (Williams and Fried 1986; Tee et al. 1995; Svaren et al. 1997; Quesada et al. 1999; Shintani et al. 1999; Ubeda et al. 1999) . For some of these gene couples, such as Stat6/Nab2 (Svaren et al. 1997) , CHOP/MetRS (Ubeda et al. 1999) , and TC3/T5B (Williams and Fried 1986) , the region of overlap is confined to a small region (about 50-100 bp) in the 3ЈUTR. This region contains an AUUUA sequence motif (ARE, AU-rich element), which represents a destabilizing sequence involved in the control of mRNA stability (Savant-Bhonsale and Cleveland 1992). It has been suggested that the in vivo formation of RNA-RNA duplexes involving ARE sequences could increase mRNA stability (Ubeda et al. 1999 ). Sequence analysis of the 100 bp-overlapping region between the CHRNA5 and CHRNA3 mRNAs did not evidence the presence of any ARE sequence motif.
Interestingly, CHRNA3 is partially coexpressed with CHRNA5 in human tissues (Flora et al. 2000b ). In the human brain, areas of maximal expression of both subunits were located in the cerebellum and thalamus. In the rat brain, no CHRNA5 expression was detected in the cerebellum, thalamus, and amygdala (Boulter et al. 1990; Wada et al. 1990 ); moreover, differences in the expression pattern of the α3 subunit between rat and primates have also been reported (Cimino et al. 1992) . In this paper, the absence of a gene overlap between CHRNA5 and CHRNA3 in the rat genome was demonstrated. The presence of species-specific differences in the regional expression of neuroreceptors is consistent with the different genomic organization of the CHRNA5/A3/B4 cluster between humans and rats.
